522 related articles for article (PubMed ID: 18785894)
21. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
22. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice.
Khalil A; Goodhand JR; Wahed M; Yeung J; Ali FR; Rampton DS
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1029-35. PubMed ID: 21857526
[TBL] [Abstract][Full Text] [Related]
24. Intravenous iron in a primary-care clinic.
Maslovsky I
Am J Hematol; 2005 Apr; 78(4):261-4. PubMed ID: 15795917
[TBL] [Abstract][Full Text] [Related]
25. Creative iron management--a practical guide.
Jenkins K
J Ren Care; 2009 Dec; 35 Suppl 2():32-5. PubMed ID: 19891684
[TBL] [Abstract][Full Text] [Related]
26. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
27. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K
Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.
Choy CK; Spencer AP; Nappi JM
Pharmacotherapy; 2007 May; 27(5):707-14. PubMed ID: 17461706
[TBL] [Abstract][Full Text] [Related]
29. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Ferrari P; Mallon D; Trinder D; Olynyk JK
Nephrology (Carlton); 2010 Apr; 15(3):344-9. PubMed ID: 20470305
[TBL] [Abstract][Full Text] [Related]
30. Caring for the renal failure patient: optimizing iron therapy.
Folkert VW; Javier AM; O'Mara NB
Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
[TBL] [Abstract][Full Text] [Related]
31. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
Sepandj F; Jindal K; West M; Hirsch D
Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
[TBL] [Abstract][Full Text] [Related]
32. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
34. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
[TBL] [Abstract][Full Text] [Related]
35. Total dose infusion of intravenous iron in patients with chronic kidney disease receiving haemodialysis.
Fenwick S; Peebles G
J Ren Care; 2011 Mar; 37(1):47-51. PubMed ID: 21288317
[TBL] [Abstract][Full Text] [Related]
36. Iron management in nondialysis-dependent CKD.
Fishbane S
Am J Kidney Dis; 2007 Jun; 49(6):736-43. PubMed ID: 17533016
[TBL] [Abstract][Full Text] [Related]
37. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Dukkipati R; Kalantar-Zadeh K
Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
[TBL] [Abstract][Full Text] [Related]
38. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
39. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
Easom A
Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
[TBL] [Abstract][Full Text] [Related]
40. Over-representation of diabetic patients with renal anaemia in the primary care setting.
Mostafa S; Tagboto S; Robinson M; Burden A; Davies S
Fam Pract; 2009 Jun; 26(3):180-2. PubMed ID: 19254968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]